eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | c syndrome |
| Comorbidity | |hypertension |
| Sentences | 124 |
| PubMedID- 20795419 | Metabolic syndrome in patients with hypertension attending a family practice clinic in jordan. |
| PubMedID- 21623724 | [possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes]. |
| PubMedID- 22304322 | [features of treatment of hypertension in patients with metabolic syndrome]. |
| PubMedID- 25615826 | Medical costs for people with obesity are approximately 30% greater than for people with normal weights, because obesity is related to serious health problems such as diabetes, hypertension, and other components of metabolic syndrome [3]. |
| PubMedID- 24466463 | hypertension is a component of metabolic syndrome, and interestingly, certain aldh2 genotypes have also been proposed as risk factors for metabolic syndrome with liver dysfunction [5]. |
| PubMedID- 22829804 | hypertension is another component of the metabolic syndrome which is independently associated with increased cardiovascular risk. |
| PubMedID- 21471972 | Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin-angiotensin-aldosterone system polymorphisms. |
| PubMedID- 20016031 | Although recent evidence underscores the role of heme-oxygenase (ho) in diabetes, its effects on insulin sensitivity and glucose metabolism in spontaneously hypertensive rat (shr), a model of essential hypertension with characteristics of metabolic syndrome including insulin resistance/impaired glucose metabolism remains largely unclear. |
| PubMedID- 20405160 | The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. |
| PubMedID- 21909069 | About 6% of patients develop hypertension due to renovascular diseases, mid-aortic syndrome, or pheochromocytoma. |
| PubMedID- 25245490 | However, it appears to be a risk factor for early onset hypertension in metabolic syndrome. |
| PubMedID- 25993638 | Increased cardiovascular mortality in subjects with metabolic syndrome is largely attributable to diabetes and hypertension in 159,971 korean adults. |
| PubMedID- 22030814 | This monosaccharide is linked to metabolic syndrome, being associated with hypertriglyceridemia, hypertension, insulin resistance and diabetes mellitus. |
| PubMedID- 21925996 | The renin-angiotensin system (ras) is a common link between hypertension and comorbidities of obesity and metabolic syndrome (mets). |
| PubMedID- 23512530 | We herein present a case of middle aortic syndrome with renovascular hypertension caused by ta in a 12-year-old male treated by an aortic stent and renal autotransplantation as a two-staged procedure. |
| PubMedID- 22555437 | Comprehensive studies, ranging from in vitro, in vivo, preclinical, to human, all suggest that attenuation of gc signaling, through 11β-hsd1 inhibition in metabolically important tissue such as the liver, is a therapeutically achievable strategy to ameliorate the glucose intolerance, obesity, fatty liver, and hypertension associated with metabolic syndrome. |
| PubMedID- 21644841 | Methods: metabolic syndrome patients with hypertension (n=28) and a control group (n=20) were given atenolol (50 mg/day) for 4 weeks. |
| PubMedID- 21107432 | The prevalence of metabolic syndrome (mets) in patients with essential hypertension is very high, and has been estimated as being close to 50%.1 hypertensive patients with mets have a much higher cardiovascular (cv) risk than their counterparts without mets,2 and also have a particularly high risk of developing type 2 diabetes mellitus (t2dm).3 in addition, the choice of antihypertensive therapy can have a large impact on the risk of development of t2dm.4 renin–angiotensin system blockers, that is, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (arbs), improve insulin sensitivity and reduce the risk of developing t2dm compared with placebo, whereas calcium channel blockers (ccbs) have a neutral effect. |
| PubMedID- 25508240 | Material and methods: we conducted an 8-week open prospective study on 36 patients with essential stage ii hypertension associated with metabolic syndrome. |
| PubMedID- 25916862 | Renin-angiotensin-aldosterone system (raas) inhibition with an ace or an arb and treatment with calcium channel blockers appears safe and well tolerated in obesity-related hypertension and in patients with metabolic syndrome. |
| PubMedID- 23629805 | Thus, shrcp are regarded as a useful model of human hypertension with metabolic syndrome. |
| PubMedID- 22728908 | Objectives: renin-angiotensin system inhibitors are preferred for the treatment of hypertension with metabolic syndrome (mets). |
| PubMedID- 24583433 | Gemcitabine induces hemolytic uremic syndrome with accelerated hypertension and raynaud's phenomenon, mimicking scleroderma renal crisis. |
| PubMedID- 22473401 | Metabolic syndrome was significantly associated with hypertension, insulin resistance, increased abdominal fat, and overweight. |
| PubMedID- 22470194 | Nafld is usually part of the metabolic syndrome, found namely in patients with diabetes mellitus, hypertension, dyslipidemia, obesity and insulin resistance, which is becoming very frequent in western populations, due to their life style (sedentariness) and diet. |
| PubMedID- 22190906 | Vascular endothelial dysfunction has been demonstrated in metabolic syndrome with and without hypertension or diabetes [1–3]. |
| PubMedID- 20383279 | Whereas arbs and acei have demonstrated their efficiency in improving insulin sensitivity and reducing end-organ damage and are now often considered as first-line therapy in hypertension with metabolic syndrome or diabetes [3], [4], [5], [30], association of anti-oxidants or anti-nitrants in an attempt to further reduce deleterious nitrative stress might be worth considering in severely affected or non-responsive patients. |
| PubMedID- 23931752 | The role of the sympathetic nervous system, stress, and hypertension in metabolic syndrome and obesity remains unclear. |
| PubMedID- 22631071 | Posterior reversible encephalopathy syndrome can be associated with severe hypertension (eg, in eclampsia or hellp syndrome), but it also has been observed without hypertension and in several clinical conditions including infections and autoimmune disorders. |
| PubMedID- 23318820 | Introduction: the treatment of arterial hypertension (ah) in patients with metabolic syndrome (ms) is a challenge, since non drug therapies are difficult to implement and optimal pharmacological treatment is not fully established. |
| PubMedID- 24958506 | Role of nitric oxide synthase uncoupling at rostral ventrolateral medulla in redox-sensitive hypertension associated with metabolic syndrome. |
| PubMedID- 24410986 | All components of metabolic syndrome, including hypertension [4,5], insulin resistance(ir) [6,7], and low hdl-c, together with high levels of tg [8,9] are frequent in patients with osas. |
| PubMedID- 21773016 | In addition, there is mounting evidence that chronic psychological stress and negative mood states are strongly associated, in a bidirectional manner, with insulin resistance, glucose intolerance, central obesity, dyslipidemia, hypertension, and other components of the metabolic syndrome [19–25]. |
| PubMedID- 22131755 | [26] furthermore, insulin-resistant patients, with and without type 2 diabetes, are at an increased risk for developing metabolic syndrome, a major cause of heart disease, hypertension and dyslipidemia. |
| PubMedID- 22988490 | Diabetes, obesity, and metabolic syndrome may lead to pulmonary hypertension through a mechanism involving hyperuricemia. |
| PubMedID- 23205504 | Exercise-induced hypertension in men with metabolic syndrome: anthropometric, metabolic, and hemodynamic features. |
| PubMedID- 24678944 | Sympathoexcitation and oxidative stress in the brain have pivotal roles in hypertension with metabolic syndrome (mets). |
| PubMedID- 20609696 | These agents may expand the utility of beta-blockers to patient populations traditionally considered not to be optimal candidates for beta-blocker therapy-a fact which has important clinical implications, because more antihypertensive agents are needed to diversify the therapeutic options available for clinicians treating hypertension in patients with the cardiometabolic syndrome or type 2 diabetes. |
| PubMedID- 25464609 | Material and methods: we conducted an 8-week open prospective study on 36 patients with essential stage ii hypertension associated with metabolic syndrome. |
| PubMedID- 22846983 | Targeting hypertension in patients with cardiorenal metabolic syndrome. |
| PubMedID- 24507240 | Did not distinguish subgroups for those with or without hypertension in the population of patients with metabolic syndrome [36]. |
| PubMedID- 25354240 | Thus, preserved stimulation of proximal tubule transport through the insulin/irs2/pi3-k pathway may play an important role in the pathogenesis of hypertension associated with metabolic syndrome. |
| PubMedID- 24658007 | Hsd11b1 enzymatic activities are thought to be involved in obesity, hypertension, and other components of the metabolic syndrome. |
| PubMedID- 23024568 | The comorbid relationship between stroke and migraine may relate to observations that migraineurs have increased adiposity, reduced insulin sensitivity, an unfavourable lipid profile and hypertension, all features of the metabolic syndrome, a known risk factor for cerebrovascular disease. |
| PubMedID- 25159084 | Very often, obstructive sleep apnea (osa) and metabolic syndrome (ms) coexist with resistant hypertension (rhtn) and may lead to diastolic dysfunction. |
| PubMedID- 22940679 | Objective: nonalcoholic fatty liver and hypertension are associated with metabolic syndrome. |
| PubMedID- 20176994 | Obese persons with metabolic syndrome often have associated with salt-sensitive hypertension, microalbuminuria, and cardiac dysfunction, and the plasma aldosterone level in one-third of metabolic syndrome patients is clearly elevated. |
| PubMedID- 25760026 | Metabolic detuning has been reported to be involved in obesity, dyslipidemia, diabetesmellitus, and hypertension, all of which characterize metabolic syndrome and are closelyassociated with insulin resistance. |
| PubMedID- 21390196 | Fifty nine had isolated metabolic syndrome (group a) and 97 had metabolic syndrome with hypertension and/or diabetes (group b). |
| PubMedID- 24729809 | All parameters of metabolic syndrome with resolving/improving t2dm, hypertension, joint disease, depressive disorders or sleep apnoea are normalized or markedly improved after lsg. |